Schonfeld Strategic Advisors LLC Increases Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN)

Schonfeld Strategic Advisors LLC raised its position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 84.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 656,100 shares of the company's stock after purchasing an additional 300,295 shares during the quarter. Schonfeld Strategic Advisors LLC owned 0.95% of Arvinas worth $12,577,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ARVN. Northern Trust Corp increased its holdings in Arvinas by 7.2% in the fourth quarter. Northern Trust Corp now owns 631,131 shares of the company's stock valued at $12,099,000 after buying an additional 42,638 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Arvinas during the fourth quarter worth about $42,332,000. Price T Rowe Associates Inc. MD boosted its holdings in Arvinas by 6.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company's stock worth $78,656,000 after buying an additional 249,295 shares during the last quarter. Hsbc Holdings PLC increased its stake in Arvinas by 22.7% during the 4th quarter. Hsbc Holdings PLC now owns 19,220 shares of the company's stock worth $365,000 after buying an additional 3,551 shares in the last quarter. Finally, MetLife Investment Management LLC raised its holdings in shares of Arvinas by 6.1% during the fourth quarter. MetLife Investment Management LLC now owns 39,437 shares of the company's stock valued at $756,000 after acquiring an additional 2,257 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company's stock.

Insider Activity at Arvinas

In other news, CEO John G. Houston sold 31,338 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the transaction, the chief executive officer now owns 1,157,480 shares of the company's stock, valued at $19,353,065.60. This represents a 2.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Noah Berkowitz sold 8,658 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the transaction, the insider now owns 110,023 shares in the company, valued at approximately $945,097.57. This trade represents a 7.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,230 shares of company stock valued at $769,402 over the last quarter. Insiders own 5.23% of the company's stock.

Analyst Upgrades and Downgrades

ARVN has been the subject of a number of research reports. Wells Fargo & Company dropped their target price on shares of Arvinas from $26.00 to $19.00 and set an "overweight" rating for the company in a report on Friday. Piper Sandler reiterated an "overweight" rating and set a $14.00 price target (down from $24.00) on shares of Arvinas in a report on Friday. Oppenheimer cut Arvinas from an "outperform" rating to a "market perform" rating in a research note on Tuesday, March 11th. BTIG Research set a $16.00 target price on shares of Arvinas and gave the stock a "buy" rating in a report on Friday. Finally, Jefferies Financial Group reissued a "hold" rating and issued a $10.00 target price (down previously from $52.00) on shares of Arvinas in a report on Friday. Eight analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $20.97.

Arvinas Stock Performance

ARVN stock traded down $0.38 during trading on Tuesday, reaching $7.25. 657,569 shares of the company were exchanged, compared to its average volume of 1,258,031. The company has a market cap of $528.97 million, a P/E ratio of -2.63 and a beta of 2.21. The stock's 50 day moving average price is $9.47 and its 200 day moving average price is $17.23. Arvinas, Inc. has a 52-week low of $5.94 and a 52-week high of $37.38.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of ($0.93) by $2.07. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. Arvinas's revenue was up 646.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.97) earnings per share. As a group, equities research analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current year.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.